Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
161 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Candidiasis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H2 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape. Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2, 22, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively. Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Candidiasis - Overview 7 Candidiasis - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Candidiasis - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Candidiasis - Companies Involved in Therapeutics Development 25 Amplyx Pharmaceuticals Inc 25 Bakker Medical Srl 25 Beta Pharma Inc 26 Biomar Microbial Technologies 26 Bionex Pharmaceuticals LLC 27 Biosergen AS 27 Cidara Therapeutics Inc 28 Dermala Inc 28 Gedea Biotech AB 29 General Biologicals Corp 29 Grupo Ferrer Internacional SA 30 Hsiri Therapeutics LLC 30 iCo Therapeutics Inc. 31 ImmunoClin Corp 31 Matinas BioPharma Holdings Inc 32 Nanomerics Ltd 32 Novabiotics Ltd 33 NovaDigm Therapeutics Inc 33 Novartis AG 34 Onxeo SA 34 Scynexis Inc 35 Sealife PHARMA GMBH 35 Viamet Pharmaceuticals Inc 36 Visterra Inc 36 Wellstat Vaccines LLC 37 Candidiasis - Drug Profiles 38 (clotrimazole + diclofenac sodium) - Drug Profile 38 61894700 - Drug Profile 39 AC-17 - Drug Profile 40 amphotericin B - Drug Profile 41 amphotericin B - Drug Profile 43 amphotericin B - Drug Profile 49 Amphotericin B sodium - Drug Profile 50 Antibody to Target Ece1 for Candidiasis - Drug Profile 52 APX-001 - Drug Profile 53 APX-001A - Drug Profile 55 arasertaconazole - Drug Profile 56 B-4010 - Drug Profile 57 BL-5923 - Drug Profile 58 BSG-005 - Drug Profile 59 candidiasis vaccine - Drug Profile 60 CD-101 - Drug Profile 61 Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 66 CLX-159 - Drug Profile 67 CSA-13 - Drug Profile 68 Drug for Candidiasis - Drug Profile 70 Drug for Oral Candidiasis - Drug Profile 71 Forazoline A - Drug Profile 72 GA-101 - Drug Profile 73 iCo-010 - Drug Profile 74 interleukin-22 - Drug Profile 75 JSM-11 - Drug Profile 76 KSL-W - Drug Profile 77 miconazole nitrate - Drug Profile 78 Monoclonal Antibodies for Candidiasis - Drug Profile 80 Monoclonal Antibody for Candidiasis - Drug Profile 81 Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 82 mutanobactin A - Drug Profile 83 NDV-3 - Drug Profile 84 NDV-3A - Drug Profile 86 NP-339 - Drug Profile 88 obliquumol - Drug Profile 89 Occidiofungin - Drug Profile 90 P-113Du - Drug Profile 91 P-113Tri - Drug Profile 92 PAC-113 - Drug Profile 93 Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 95 Prof-002 - Drug Profile 96 Recombinant Enzyme for Candidiasis - Drug Profile 97 Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 98 SCY-078 - Drug Profile 99 SLP-0901 - Drug Profile 107 SLP-0904 - Drug Profile 108 Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 109 Small Molecule for Candidiasis - Drug Profile 110 Small Molecule for Fungal Infections - Drug Profile 111 Small Molecules for Aspergillosis and Candidiasis - Drug Profile 112 Small Molecules for Candidiasis - Drug Profile 113 Small Molecules for Candidiasis - Drug Profile 114 Small Molecules for Candidiasis - Drug Profile 115 Small Molecules for Fungal Infections - Drug Profile 116 Small Molecules for Fungal Infections - Drug Profile 117 Small Molecules for Systemic Candidiasis - Drug Profile 118 Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 119 Synthetic Peptides for Candidiasis - Drug Profile 120 Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 121 TOL-463 - Drug Profile 122 Vaccine to Target Ece1 for Candidiasis - Drug Profile 123 Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile 124 VIS-FNG - Drug Profile 125 voriconazole - Drug Profile 126 VT-1129 - Drug Profile 127 VT-1161 - Drug Profile 129 VT-1598 - Drug Profile 136 Candidiasis - Dormant Projects 138 Candidiasis - Discontinued Products 141 Candidiasis - Product Development Milestones 142 Featured News & Press Releases 142 Appendix 155 Methodology 155 Coverage 155 Secondary Research 155 Primary Research 155 Expert Panel Validation 155 Contact Us 155 Disclaimer 156
List of Tables
Number of Products under Development for Candidiasis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2017 Candidiasis - Pipeline by Bakker Medical Srl, H2 2017 Candidiasis - Pipeline by Beta Pharma Inc, H2 2017 Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2017 Candidiasis - Pipeline by Bionex Pharmaceuticals LLC, H2 2017 Candidiasis - Pipeline by Biosergen AS, H2 2017 Candidiasis - Pipeline by Cidara Therapeutics Inc, H2 2017 Candidiasis - Pipeline by Dermala Inc, H2 2017 Candidiasis - Pipeline by Gedea Biotech AB, H2 2017 Candidiasis - Pipeline by General Biologicals Corp, H2 2017 Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H2 2017 Candidiasis - Pipeline by Hsiri Therapeutics LLC, H2 2017 Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2017 Candidiasis - Pipeline by ImmunoClin Corp, H2 2017 Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H2 2017 Candidiasis - Pipeline by Nanomerics Ltd, H2 2017 Candidiasis - Pipeline by Novabiotics Ltd, H2 2017 Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H2 2017 Candidiasis - Pipeline by Novartis AG, H2 2017 Candidiasis - Pipeline by Onxeo SA, H2 2017 Candidiasis - Pipeline by Scynexis Inc, H2 2017 Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2017 Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H2 2017 Candidiasis - Pipeline by Visterra Inc, H2 2017 Candidiasis - Pipeline by Wellstat Vaccines LLC, H2 2017 Candidiasis - Dormant Projects, H2 2017 Candidiasis - Dormant Projects, H2 2017 (Contd..1), H2 2017 Candidiasis - Dormant Projects, H2 2017 (Contd..2), H2 2017 Candidiasis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
